Clearmind Medicine (CMND) announced the launch of its Electronic Data Capture, EDC, system to support its Phase I/II clinical trial of its MEAI-based treatment for Alcohol Use Disorder, AUD. The activation of the EDC system marks a critical operational milestone, enabling real-time, secure and compliant data collection across all stages of the study. The EDC system enables seamless data collection and real-time monitoring across all participating sites. The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in individuals with AUD.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Exclusive talk with retreat provider ONE Retreats
- Psychedelic: Exclusive talk with biotech company Clearmind Medicine
- Clearmind Medicine says CMND-100 arrives in the U.S.
- Psychedelic: atai Life Sciences, NRx report quarterly results
- Clearmind signs non-binding LOI with Polyrizon for intranasal drug delivery